Table 1.
Interferon therapy for dual hepatitis B and C viruses infection
| Author | Case no. | HBeAg(+)/HBV DNA(+) | Study type | Type of interferon | VR-EOT | VR-EFU | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rx | Cont | Rx | Cont | |||||||
| HBVa | HCV | HBV | HCV | |||||||
| Weltman [28], Australia | 8 | 1 (13%)/NA | OL | IFN-α2b 3 MU tiw ×6 M | 2 (25%)b | NA | NA | 1 (13%)b | NA | NA |
| Liaw [29], Taiwan | 15 | 15 (100%)/15 (100%) | RCT | IFN-L 4–6 MU/m2 or IFN-α2a 9 MU tiw ×12 W | NA | HCV(–) | ||||
| 1 (7%)/1 (7%) | NA | 46/164 (28%) | ||||||||
| Mazzella [30], Italy | 5 | 5 (100%)/5 (100%) | CC | IFN-L 5 MU/m2 tiw ×6 M | 3 (60%)/2 (40%) | 0 | 1/2 (50%)/0 | NA | ||
| Guptan [31], India | 7 | 3 (43%)/7 (100%) | OL | IFN-α2b 6 MU tiw ×6 M | NA/6 (86%) | 2 (29%) | NA | NA/7 (100%) | 2 (29%) | NA |
| Villa [32], Italy | 30 | 6 MU 0/2 (14%) |
RCT | IFN-α 6 MU tiw ×6 M n = 14 |
6 MU 0/0 |
10 (71%) |
6 MU 0/0 |
0 |
||
| 9 MU 0/4 (25%) |
IFN-α 9 MU tiw ×6 M n = 16 |
9 MU 0/4 (100%) |
14 (87%) |
9 MU 0/4 (100%) |
5 (31%) |
|||||
Note: VR, virological response; EOT, end of treatment; EFU, end of follow-up; Rx, treatment; Cont, control; NA, not available; RCT, randomized controlled trial; OL, open-label; CC, case control study; MU, mega-unit; tiw, thrice per week; IFN: interferon; 6 M: 6 months treatment
aData expressed as HBeAg(–)/HBV DNA(–)
bBiochemical response